The Jackson Laboratory

2017 Presenters

arrow

close
info:
Featured Speaker: Francis Collins, M.D., Ph.D.
arrow

Featured Speaker: Francis Collins, M.D., Ph.D.

Director, National Institutes of Health
close
info:
Content
arrow

close
info:
Content
Mark Adams. Ph.D.
arrow

Mark Adams. Ph.D.

Professor and Campus Director, J. Craig Venter Institute
close
info:
Dr. Mark Adams is Professor and Campus Director for the J. Craig Venter Institute in La Jolla, California. Dr. Adams comes from a rich background including industry, government, academic, and nonprofit settings. Dr. Adams was one of the founding scientists of The Institute for Genomic Research and of Celera Genomics, where he directed the large-scale sequencing and genome annotation groups. At JCVI he leads the bacterial genomics programs with a particular emphasis on evolutionary approaches to understanding the spread of multidrug-resistant bacteria.
Lisa Alderson
arrow

Lisa Alderson

President and CEO, Genome Medical
close
info:
Lisa Alderson is President and CEO of Genome Medical, a specialty medical practice and genomic services network delivering genome-centered patient care and physician education services. Previously she was co-founder and partner of Tech Care Now and chief commercial officer and strategy officer for Invitae. She received her MBA from Harvard Business School.
Nir Barzilai, M.D.
arrow

Nir Barzilai, M.D.

Professor and Ingeborg and Ira Leon Rennert Chair in Aging Research Director, Institute for Aging Research
close
info:
Morris Birnbaum, M.D., Ph.D.
arrow

Morris Birnbaum, M.D., Ph.D.

Senior Vice President and Chief Scientific Officer, Cardiovascular and Metabolic Disease Research Unit, Pfizer
close
info:
Morris J. Birnbaum, M.D., Ph.D. is Senior Vice President and Chief Scientific Officer of the Cardiovascular and Metabolic Disease (CVMED) Research Unit at Pfizer, which focuses on developing therapies to treat, slow or prevent disease progression and improve the quality of life of patients with obesity, type 2 diabetes (T2D), cardiovascular (CV) and kidney diseases. Dr. Birnbaum is a leading researcher in the signals that regulate and integrate metabolic pathways in liver, muscle and adipose tissue, and how they are disrupted in insulin resistant states.Dr. Birnbaum completed his undergraduate, graduate and medical training at Brown University in Providence, R.I. before moving to San Francisco for postdoctoral studies at the University of California. Following an associate professorship at Harvard Medical School, he went to the University of Pennsylvania as professor of Medicine. Dr. Birnbaum is currently the associate dean for Biomedical Cores and associate director of the Institute for Diabetes, Obesity and Metabolism. He was elected to membership in the Association of American Physicians in 2003 and made a fellow of the AAAS in 2007.
Bharatt Chowrira, Ph.D., J.D.
arrow

Bharatt Chowrira, Ph.D., J.D.

President and Chief of Business and Strategy, PureTech Health
close
info:
Dr. Bharatt Chowrira is President and Chief of Business and Strategy at PureTech Health. Dr. Chowrira was most recently the President of Synlogic, a Cambridge, MA-based biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, where he oversaw and managed corporate and business development, alliance management, financial, HR, IP, and legal operations. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals, which was acquired by Teva Pharmaceuticals in the Spring of 2015 for $3.5 billion. He has held various leadership and management positions at Nektar Therapeutics, Merck & Co., Sirna Therapeutics (acquired by Merck & Co. for $1.1 billion) and Ribozyme Pharmaceuticals.
Nancy Cox, Ph.D.
arrow

Nancy Cox, Ph.D.

Director, Vanderbilt Genetics Institute; Director, Division of Genetic Medicine; Mary Phillips Edmonds Gray Professor of Genetics
close
info:
Dr. Nancy Cox is a quantitative human geneticist with a long-standing research program in identifying and characterizing the genetic component to common human diseases; current research is focused on large-scale integration of genomic with other “-omics” data as well as biobank and electronic medical records data.
Anthony Elias, M.D.
arrow

Anthony Elias, M.D.

Professor of Medicine, University of Denver, Colorado
close
info:
Content
Anthony B. Evnin, Ph.D.
arrow

Anthony B. Evnin, Ph.D.

Partner, Venrock
close
info:
Dr. Evnin is a partner at Venrock, a venture capital firm, and on the Board of Directors of AVEO Pharmaceuticals, Infinity Pharmaceuticals, Juno Therapeutics and Constellation Pharmaceuticals and formerly a director of over 35 other biotech companies. He is a trustee of The Jackson Laboratory; member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center and of the Board of Directors of the Albert and Mary Lasker Foundation; director of the New York Genome Center; and Trustee Emeritus of The Rockefeller University and of Princeton University. He received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Andrew A.F. Hack, M.D., Ph.D.
arrow

Andrew A.F. Hack, M.D., Ph.D.

Chief Financial Officer, Editas Medicine
close
info:
Andrew A. F. Hack, M.D., Ph.D., has served as Chief Financial Officer of Editas Medicine since July 2015. Prior to joining Editas, from May 2011 to June 2015, Dr. Hack was a portfolio manager at Millennium Management LLC, an institutional asset manager, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium Management, Dr. Hack was a healthcare analyst at HealthCor Management, L.P., a registered investment advisor, from December 2008 to May 2011. Prior to HealthCor, Dr. Hack served as a healthcare analyst for hedge fund Carlyle-Blue Wave Partners and as principal of the MPM BioEquities Fund, a hedge fund that was affiliated with MPM Capital. Dr. Hack began his investment career covering the biotechnology sector at investment banks Banc of America Securities LLC and Rodman & Renshaw, LLC. Dr. Hack co-founded Reify Corporation, a life science tools and drug discovery company. Dr. Hack serves as a director of Mersana Therapeutics, Inc., a private company. Dr. Hack received his B.A. in biology with special honors from the University of Chicago, where he also received his M.D. and Ph.D.
Julian Harris, M.D., M.B.A.
arrow

Julian Harris, M.D., M.B.A.

President, CareAllies
close
info:
Content
George Kuchel, M.D.
arrow

George Kuchel, M.D.

Professor and Travelers Chair in Geriatrics and Gerontology/Director, UConn Center on Aging, UConn Health
close
info:
David Ledbetter, Ph.D, FACMG
arrow

David Ledbetter, Ph.D, FACMG

Executive Vice President and Chief Scientific Officer, Geisinger Health System
close
info:
Executive Vice President and Chief Scientific Officer at Geisinger Health System. He came to Geisinger from Atlanta’s Emory University School of Medicine where he was the Robert W. Woodruff Professor and Director of the Division of Medical Genetics in the Department of Human Genetics.
Andrew Lo, Ph.D.
arrow

Andrew Lo, Ph.D.

Professor of Finance, and Director, Laboratory for Financial Engineering, MIT Sloan School of Management
close
info:
Dr. Lo's research interests include the empirical validation and implementation of financial asset pricing models; hedge-fund risk and return dynamics and risk transparency; and, most recently, evolutionary and neurobiological models of individual risk preferences and financial markets.
Anita McGahan, Ph.D.
arrow

Anita McGahan, Ph.D.

Rotman Chair in Management, Professor of Strategic Management, University of Toronto
close
info:
Dr. McGahan is professor and Rotman chair in Management at the Rotman School of Management at the University of Toronto. She is cross appointed to the Munk School of Global Affairs and the Physiology Department of the Medical School; is senior associate at the Institute for Strategy and Competitiveness at Harvard University; is the chief economist in the Division of Health and Human Rights at the Massachusetts General Hospital; and is president of the Academy of Management. Dr. McGahan earned both her Ph.D. and A.M. at Harvard University. She holds an M.B.A. from Harvard Business School, and a BA from Northwestern University. She also spent several years at both McKinsey & Company and Morgan Stanley & Company and was previously on the faculties of both Harvard Business School and Boston University. Her credits include three books and over 100 articles, case studies, notes and other published material on competitive advantage, industry evolution, and financial performance. Her current research emphasizes entrepreneurship in the public interest and innovative collaboration between public and private organizations. In 2010, she was awarded the Academy of Management BPS Division’s Irwin Distinguished Educator Award and, in 2012, the Academy conferred on McGahan its Career Distinguished Educator Award. In 2012 she was elected a Fellow of the Strategic Management Society, and in 2015 she was elected a Fellow of the Academy of Management.
S. Jay Olshansky, Ph.D.
arrow

S. Jay Olshansky, Ph.D.

Professor, School of Public Health, Division of Epidemiology and Biostatistics, University of Illinois at Chicago/Co-Founder and Chief Scientist, Lapetus Solutions, Inc.
close
info:
David Sabow
arrow

David Sabow

Managing Director, Head of Life Science & Healthcare, Silicon Valley Bank
close
info:
David Sabow is a managing director and serves as the head of Silicon Valley Bank’s life science and healthcare practice in the U.S. With more than 15 years of life science and healthcare finance experience, David’s background spans IPOs, follow-on offerings, mergers & acquisitions, senior and subordinated debt, and strategic advisory roles across the life science and healthcare finance sector. David is a frequent speaker at venture capital and life science industry conferences around the world. Recent speaking engagements include the CanceRX meeting at MIT, the BioEnterprise Conference in Cleveland, the Sachs Associates Biotech in Europe Forum in Basel Switzerland, and the Medical Device and Diagnostics Conference in Shanghai. Prior to joining Silicon Valley Bank, David spent almost nine years in the life science investment banking practice at Canaccord Genuity, where he participated in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. While at Canaccord, David worked on both domestic and international transactions across the spectrum of life science and healthcare. Before Canaccord, David worked as a relationship manager with U.S. Bank. David graduated with high distinction from Santa Clara University.
Alan Sachs, M.D., Ph.D.
arrow

Alan Sachs, M.D., Ph.D.

Chief Scientific Officer, Thermo Fisher Scientific
close
info:
Alan Sachs is the Chief Scientific Officer for Thermo Fisher Scientific. He served as the Chief Scientific Officer for Life Technologies/Life Sciences Solutions Group within Thermo Fisher between 2012 and 2015. Prior to this role, Dr. Sachs was the Vice President of Exploratory and Translational Sciences at Merck Research Laboratories. During his ten years at Merck, he built and directed the global RNA Therapeutics Department, led the Rosetta Inpharmatics group, and led the Department of Molecular Profiling. Before joining Merck, Dr. Sachs was an Associate Professor of Molecular and Cell Biology at the University of California at Berkeley, and a Whitehead Institute Fellow at the Whitehead Institute in Cambridge, MA. Dr. Sachs’ academic work focused on understanding of the role of the poly(A) tail in translation and mRNA stability. Dr. Sachs graduated from Cornell University with a B.A. in Biochemistry, received his Ph.D. with Roger Kornberg in Cell Biology at Stanford Medical School, received his M.D. from Stanford Medical School, and completed a post-doctoral fellowship with Ron Davis in the Department of Biochemistry, Stanford Medical School.
Eric Schadt, Ph.D.
arrow

Eric Schadt, Ph.D.

Professor and Chair, Mount Sinai
close
info:
Michael Snyder, Ph.D.
arrow

Michael Snyder, Ph.D.

Stanford W. Ascherman Professor and Chair, Department of Genetics and Director, Center for Genomics and Personalized Medicine, Stanford University
close
info:
Content
Andrew Ury, M.D.
arrow

Andrew Ury, M.D.

Founder and Chairman/CEO, ActX
close
info:
Content